These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7659211)

  • 1. Clinical predictors in the evaluation of a pelvic mass.
    Smikle CB; Lunt CC; Hankins GD
    Mil Med; 1995 May; 160(5):233-5. PubMed ID: 7659211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we preoperatively risk stratify ovarian masses for malignancy?
    Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
    J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
    Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
    Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preoperative identification of malignancy among women with a pelvic mass. Evaluation of a risk index based on ultrasound findings. CA 125 in serum and menopausal status].
    Hagen B; Tingulstad S; Onsrud M; Moen M; Kiserud T; Eik-Nes S; Halvorsen T; Nustad K
    Tidsskr Nor Laegeforen; 1995 Mar; 115(7):820-2. PubMed ID: 7701488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors].
    Smoleń A; Stachowicz N; Czekierowski A; Kotarski J
    Ginekol Pol; 2010 Apr; 81(4):254-61. PubMed ID: 20476596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing benign and malignant pelvic masses: the value of different diagnostic methods in everyday clinical practice.
    Engelen MJ; Bongaerts AH; Sluiter WJ; de Haan HH; Bogchelman DH; Tenvergert EM; Willemse PH; van der Zee AG
    Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):94-101. PubMed ID: 17118522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Hypercoagulable State for Predictive Ovarian Malignancy in Women with a Pelvic Mass.
    Yanaranop M
    J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S148-56. PubMed ID: 29927556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Management of Adnexal Masses.
    Biggs WS; Marks ST
    Am Fam Physician; 2016 Apr; 93(8):676-81. PubMed ID: 27175840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of referral guidelines for women with pelvic masses.
    Im SS; Gordon AN; Buttin BM; Leath CA; Gostout BS; Shah C; Hatch KD; Wang J; Berman ML
    Obstet Gynecol; 2005 Jan; 105(1):35-41. PubMed ID: 15625139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
    Roman LD; Muderspach LI; Burnett AF; Morrow CP
    J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative assessment of ovarian tumors by CA 125 measurement and transvaginal color Doppler ultrasound.
    Kupesić S; Vujisić S; Kurjak A; Mihaljević D; Radosević S
    Acta Med Croatica; 2002; 56(1):3-10. PubMed ID: 12455447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical assessment, gross examination, frozen section of ovarian masses: do patients benefit?
    Ghaemmaghami F; Fakour F; Karimi Zarchi M; Behtash N; Modares Gilani M; Mousavi A; Shariat M
    Arch Gynecol Obstet; 2008 Sep; 278(3):209-13. PubMed ID: 18259768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
    Antonić J; Rakar S
    Anticancer Res; 1995; 15(4):1527-32. PubMed ID: 7654041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk of malignancy index in preoperative diagnosis of ovarian cancer.
    Ma S; Shen K; Lang J
    Chin Med J (Engl); 2003 Mar; 116(3):396-9. PubMed ID: 12781045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of a risk of malignancy index in preoperative diagnosis of ovarian cancer].
    Ma S; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2001 Mar; 36(3):162-4. PubMed ID: 11783394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass.
    Yanaranop M; Tiyayon J; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
    Gynecol Oncol; 2016 Jun; 141(3):479-484. PubMed ID: 26996662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.